Last reviewed · How we verify
Intramuscular influenza vaccine
Intramuscular influenza vaccine is a Inactivated influenza vaccine Biologic drug developed by The University of Hong Kong. It is currently in Phase 3 development for Influenza prevention in adults and/or pediatric populations.
This intramuscular influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains.
This intramuscular influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains. Used for Influenza prevention in adults and/or pediatric populations.
At a glance
| Generic name | Intramuscular influenza vaccine |
|---|---|
| Sponsor | The University of Hong Kong |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated influenza virus antigens that are administered intramuscularly to trigger both humoral (antibody-mediated) and cellular immune responses. This prepares the immune system to recognize and neutralize circulating influenza viruses, reducing infection risk and disease severity. The University of Hong Kong's formulation is in phase 3 development, likely investigating improved immunogenicity or broader strain coverage compared to existing vaccines.
Approved indications
- Influenza prevention in adults and/or pediatric populations
Common side effects
- Injection site pain, erythema, or swelling
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (PHASE3)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Vaccine Pandemic Preparedness Through Airway Immunology Characterization (EARLY_PHASE1)
- A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine (PHASE1)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) (PHASE1, PHASE2)
- A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intramuscular influenza vaccine CI brief — competitive landscape report
- Intramuscular influenza vaccine updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI
Frequently asked questions about Intramuscular influenza vaccine
What is Intramuscular influenza vaccine?
How does Intramuscular influenza vaccine work?
What is Intramuscular influenza vaccine used for?
Who makes Intramuscular influenza vaccine?
What drug class is Intramuscular influenza vaccine in?
What development phase is Intramuscular influenza vaccine in?
What are the side effects of Intramuscular influenza vaccine?
Related
- Drug class: All Inactivated influenza vaccine drugs
- Manufacturer: The University of Hong Kong — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Influenza prevention in adults and/or pediatric populations
- Compare: Intramuscular influenza vaccine vs similar drugs
- Pricing: Intramuscular influenza vaccine cost, discount & access